Literature DB >> 19055178

Use of recombinant factor VILa in Operation Iraqi Freedom and Operation Enduring Freedom: survey of Army surgeons.

Ronald J Kembro1, John D Horton, Michel Wagner.   

Abstract

Military physicians are using recombinant factor VIIa (rFVIIa) in Iraq and Afghanistan to help stop life-threatening hemorrhage in trauma patients. We constructed a questionnaire and surveyed Army general surgeons deployed to Iraq and/or Afghanistan about their predeployment experience, deployment experience, and projected postdeployment practice regarding rFVIIa usage. Most surgeons had rFVIIa available during their deployment (65%). The drug was used with varying frequency and subjective therapeutic effect. A majority of surgeons (79%) were unaware of any guideline or policy governing the use of rFVIIa. Seventy percent of respondents would use the drug in their future practice. Deployed surgeons generally have positive attitudes regarding the use of rFVIIa, but greater guidance and outcome measures are needed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19055178     DOI: 10.7205/milmed.173.11.1057

Source DB:  PubMed          Journal:  Mil Med        ISSN: 0026-4075            Impact factor:   1.437


  3 in total

1.  Recombinant activated factor VII in controlling bleeding in non-hemophiliac patients.

Authors:  Farjah H AlGahtani; Mashael Alshaikh; AbdulRehman AlDiab
Journal:  Ann Saudi Med       Date:  2010 May-Jun       Impact factor: 1.526

2.  Hemostatic Nanoparticles Improve Survival Following Blunt Trauma Even after 1 Week Incubation at 50 °C.

Authors:  Margaret Lashof-Sullivan; Mark Holland; Rebecca Groynom; Donald Campbell; Andrew Shoffstall; Erin Lavik
Journal:  ACS Biomater Sci Eng       Date:  2016-01-18

3.  Engineering Intravenously Administered Nanoparticles to Reduce Infusion Reaction and Stop Bleeding in a Large Animal Model of Trauma.

Authors:  Chimdiya Onwukwe; Nuzhat Maisha; Mark Holland; Matt Varley; Rebecca Groynom; DaShawn Hickman; Nishant Uppal; Andrew Shoffstall; Jeffrey Ustin; Erin Lavik
Journal:  Bioconjug Chem       Date:  2018-07-09       Impact factor: 4.774

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.